WESTON,
Fla., June 15, 2023 /PRNewswire/ -- Cantex
Pharmaceuticals, Inc., a clinical-stage pharmaceutical company
focused on developing transformative therapies for cancer and
other life-threatening medical conditions for which new treatments
are urgently needed, today announced that it will present at the
MedInvest Oncology Investor Conference being held June 21-22, 2023, in Boston, MA.
Stephen G. Marcus, M.D. Cantex's
Chief Executive Officer, will present a corporate overview to
strategics/big Pharma, VCs, family offices, hedge funds, and
government/non-profit grant makers on Thursday, June 22 at 11:10
a.m. ET, at the offices of Goodwin Procter LLP, 100 Northern
Ave., Boston, MA 02210,
17th Floor. Dr. Marcus will also be available for
one-on-one meetings at the conference.
Those interested in meeting with Cantex can register using the
conference
website: https://www.medinvestconferences.com/register or by
requesting a meeting through any of the contacts below.
About Azeliragon
Azeliragon is an orally administered
capsule, taken once daily, that inhibits interactions of the
receptor for advanced glycation endproducts (known as RAGE)
with certain ligands, including HMGB1 and S100 proteins in the
tumor microenvironment. Azeliragon was originally under development
for Alzheimer's disease by vTv Therapeutics Inc. (NASDAQ: VTVT)
from which Cantex licensed worldwide rights to azeliragon. Clinical
safety data from these trials, involving more than 2000 individuals
dosed for periods up to 18 months, indicate that azeliragon is very
well tolerated. Cantex has ongoing clinical trials in
metastatic pancreatic cancer, neoadjuvant therapy of breast cancer,
and hospitalized COVID patients to prevent acute kidney injury, and
will soon initiate FDA-approved phase 2 clinical trials of
azeliragon in newly diagnosed glioblastoma, and in brain metastases
in combination with stereotactic radiosurgery. These trials are
based on robust pre-clinical data as well as the extensive clinical
safety information from randomized placebo-controlled clinical
trials.
About Cantex Pharmaceuticals, Inc.
Cantex
Pharmaceuticals, Inc. is a privately held, clinical-stage
pharmaceutical company focused on developing transformative
therapies for cancer and other life-threatening medical conditions
for which new treatments are urgently needed. For more information,
please visit www.cantex.com.
Contact:
Tiberend Strategic Advisors, Inc.
Investors
Daniel
Kontoh-Boateng
+1 862-213-1398
dboateng@tiberend.com
Media
Casey McDonald
+1 646-577-8520
cmcdonald@tiberend.com
Cantex Pharmaceuticals, Inc.
Stephen G. Marcus, M.D.
+1 954-315-3660
smarcus@cantex.com
Juan F. Rodriguez
+1 954-315-3660
jrodriguez@cantex.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/cantex-pharmaceuticals-to-present-at-the-medinvest-oncology-investor-conference-in-boston-301851424.html
SOURCE Cantex Pharmaceuticals, Inc.
